cdT cells constitute a small proportion of lymphocytes in peripheral blood. Unlike abT cells, the anti-tumor activities are exerted through several different pathways in a MHC-unrestricted manner. Thus, immunotherapy using cdT cells is considered to be effective for various types of cancer. Occasionally, however, ex vivo expanded cells are not as effective as expected due to cell exhaustion. To overcome the issue of T-cell exhaustion, researchers have generated induced pluripotent stem cells (iPSCs) that harbor the same T-cell receptor (TCR) genes as their original T-cells, which provide nearly limitless sources for antigen-specific cytotoxic T lymphocytes (CTLs). However, these technologies have focused on abT cells and require a population of antigen-specific CTLs, which are purified by cell sorting with HLA-peptide multimer, as the origin of iPS cells. In the present study, we aimed to develop an efficient and convenient system for generating iPSCs that harbor rearrangements of the TCRG and TCRD gene regions (cdT-iPSCs) without cell-sorting. We stimulated human whole peripheral blood mononuclear cell (PBMC) culture using Interleukin-2 and Zoledronate to activate cdT cells. Gene transfer into those cells with the Sendai virus vector resulted in cdT cell-dominant expression of exogenous genes. The introduction of reprogramming factors into the stimulated PBMC culture allowed us to establish iPSC lines. Around 70% of the established lines carried rearrangements at the TCRG and TCRD gene locus. The cdT-iPSCs could differentiate into hematopoietic progenitors. Our technology will pave the way for new avenues toward novel immunotherapy that can be applied for various types of cancer. STEM CELLS TRANSLATIONAL MED-ICINE 2018;7:34-44
INTRODUCTION
gdT cells are a small subset of T lymphocytes that express T-cell receptors (TCRs) that are distinct from those expressed on the surface of abT cells, a major subset of T lymphocytes [1] [2] [3] . Among them, Vg9Vd2 T cells represent the major gdT cell subtype in human peripheral blood [4] . There is substantial evidence to suggest that they represent an important player in the immune system's arsenal of effector cells and, that they have antitumor activity [5] . Unlike abT cells, Vg9Vd2 T cells exhibit MHC-unrestricted lytic activity against a wide variety of tumor cells [6, 7] , because they recognize tumor ligands outside of MHC restriction. Thus, Vg9Vd2 T cells can exert potent cytotoxic effects against cancer with the reduced expression-or even in the absence-of human leukocyte antigen (HLA) [8] . Additionally, the activation of gd-TCRs promotes gdT cell-cytotoxicity through several different pathways, depending on granule exocytosis, the death receptor pathway and the secretion of cytokines [9] [10] [11] [12] . For these reasons, immune therapy with Vg9Vd2 T cells is considered to be effective in the clinical setting.
There have been several clinical trials on the adoptive transfer of ex vivo expanded Vg9Vd2T cells into cancer patients [13] [14] [15] [16] [17] [18] . The results of these trials revealed that adoptively transferred gdT cells are well tolerated by patients and that they can be safely used as immunotherapy. However, ex vivo expanded cells are occasionally not as effective as expected because long-term stimulation drives tumorspecific cytotoxic T lymphocytes (CTLs) toward a state of terminal differentiation and exhaustion [19, 20] .
This limitation can be overcome by the use of induced pluripotent stem cells (iPSCs) [21] [22] [23] . iPSCs possess the property of unlimited self-renewal and multi-lineage differentiation potential [24] . Thus, T cells differentiated from iPSCs could become a source of near limitless and rejuvenated immune cells. In fact, recent studies have revealed that mature human T cells can be reprogrammed into iPSCs that can redifferentiate in vitro into functional T lymphocytes that express the same antigen-specific TCR as their original cells [21] [22] [23] . However, these previous technologies focused on abT cells and required a population of CTLs that express a certain antigen-specific TCR as the origin of the iPSCs and it was necessary to purify the cells by HLA-peptide multimer selection.
In the present study, we established a simple and efficient method of generating iPSCs from human Vg9Vd2T cells without the use of HLA-peptide multimer or antibodies and confirmed that the iPSC line could redifferentiate into the hematopoietic lineage. This technology may provide a therapeutic cell source for novel adoptive cell therapies.
MATERIALS AND METHODS
cdT Cell-Stimulating Culture of Whole PBMCs
Human gdT cells in whole peripheral blood mononuclear cell (PBMC) culture were activated according to a previously reported protocol, with slight modifications [9] . Firstly, PBMCs were separated from whole blood samples using BD vacutainer blood collection tubes with sodium heparin (BD, Tokyo, Japan). Informed consent was obtained for the collection of whole blood from healthy volunteers. Subsequently, the PBMC cultures were stimulated with 5 mM zoledronic acid (Novartis, Basel, Switzerland) in RPMI 1640 medium (Life Technologies, Waltham, MA) supplemented with 10% fetal bovine serum (Life Technologies), 1.0 3 10 25 M 2Me (Nacalai Tesque, Kyoto, Japan), 100 U/ml penicillin and 100 mg/ml streptomycin (Life Technologies) at the beginning of culturing. One milliliter of the cell suspension was seeded in the wells of 24-well multi-culture dishes (Nunc, Waltham, MA) at a density of 1 3 10 6 /ml and cultivated at 378C in a humidified atmosphere containing 5% CO 2 .
From day 1, 100 IU/ml human recombinant IL-2 (Shionogi Pharmaceuticals, Osaka, Japan) was added every day. Thereafter, the cultured cells were passed at a ratio of 1:2 into new wells every 2-3 days according to the degree of cellular proliferation. The cultured cells were analyzed at the indicated time points by flow cytometry.
Flow Cytometry
The cells were stained with monoclonal antibodies (mAb) and analyzed using a FACS Verse (Becton Dickinson, Franklin Lakes, NJ). The following mAbs were used for the phenotypic analysis: eFluor450-labeled anti-CD3 (eBiosciences, San Diego, CA, 48-0037-41), PECy7-labeled anti-CD3 (BD PharMingen, San Diego, CA, 563423), FITC-labeled anti-TCR Vg9 (Beckman Coulter, Brea, CA, IM1463), Human APJ APC-conjugated antibody (R&D systems, Minneapolis, MN, FAB856A), APC anti-human CD34 (Biolegend, San Diego, CA, 343608) and Anti-Human CD43 PE (eBioscience, 12-0439).
On days 4 and 12 in hematopoietic differentiation, the cells were treated with 500 ml of Accutase at 378C for 15 minutes and washed with 1% BSA in PBS after centrifuging, followed by reactions with antibodies. On day 12, the dissociated cells were resuspended in StemPro34 medium and plated onto plastic at 378C for 1 hour, and the floating cells were collected to remove any adherent cells. Dead cells were excluded by 7-AAD staining.
Generation of iPSCs from Human cdT Cell Culture
Stimulated PBMCs (1 3 10 4 cells) were suspended in 100 ll of gdT cell medium with CytoTune-iPS 2.0 (DNAVEC, Tokyo, Japan, DV-0304-3) containing 2 type of Sendai viruses each of which individually encoded KLF4 and c-MYC, and 1 type of Sendai virus that polycistronically encoded OCT3/4, KLF4, and SOX2 at an MOI of 10-30 and cultivated in a 96-well plate. Twenty-four hours later, the cells were plated on a 6-well plate precoated with the recombinant laminin-511 E8 fragments (iMatrix-511, Nippi, Tokyo, Japan). On days 3, 5, and 7 after transduction, an additional 1 ml of hiPSC medium (Stem Fit, Ajinomoto, Tokyo, Japan) was added to the culture. From day 9, the hiPSC medium was changed every two days. From day 21, we started to pick up and expand colonies.
Human iPSCs Culture
We cultured the established iPSCs according to a previously described method [25] . Briefly, the culture plates were precoated with recombinant laminin-511 E8 fragments (iMatrix-511, Nippi) (0.5mg/cm 2 ), and the iPSCs were cultured in Stem Fit medium (Ajinomoto) at 378C with 5% CO 2 . The medium was changed every other day and was passaged every 7-10 days using 0.53 TrypLE Select (13 TrypLE Select diluted 1:1 with 0.5 mM EDTA/PBS(-), Life technologies) and Rock inhibitor (Y-27632, WAKO, Osaka, Japan).
TCRG and TCRD Gene Rearrangement in iPSCs Derived from cdT Cell
To analyze the rearrangement of the TCRG and TCRD gene regions, cultured cells were lysed with a cell lysis solution (QIAGEN, Venlo, Netherlands) and treated with proteinase K. DNA was then extracted using a phenol-chloroform extraction-based method followed by ethanol precipitation. A polymerase chain reaction (PCR) was performed according to the previous reports [26, 27] using the primers shown in Supporting Information Table S1 . The amplified products were identified by 2% agarose gel electrophoresis and the dominant band within the expected size range was purified using a QIAquick gel-extraction kit (QIAGEN). Direct sequencing was performed using a BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Waltham, MA) and an ABI 3130 genetic analyzer (Applied Biosystems) according to the manufacturer's instructions. Thereafter, these data were confirmed by capillary electrophoresis. Capillary electrophoresis was performed using the TCRB and TCRG T cell Clonality Assay Kit (InVivoScribe, San Diego, CA) according to the manufacturer's instructions. The PCR samples were electrophoresed on an ABI 3130 genetic analyzer and the results were analyzed using the GeneMapper software program (Applied Biosystems).
RT-PCR and qRT-PCR
To test the expression of pluripotent genes in gdT cell-derived iPSC clones, total RNA was extracted using TRIzol reagent (Life technologies) and treated with a Turbo DNA-free kit (Life technologies) to remove genomic DNA contamination. Five hundred Watanabe, Koyanagi-Aoi, Taniguchi-Ikeda et al. 35 www.StemCellsTM.com O c 2017 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by nanograms of total RNA was reverse transcribed to singlestranded cDNA using a PrimeScript II 1st Strand Synthesis Kit (Takara, Shiga, Japan) with oligo-dT primers according to the manufacturer's instructions. A quantitative PCR was performed using SYBR Premix Ex Taq (TaKaRa) on a 7500 Real-Time PCR System (Applied Biosystems). Each sample was analyzed in triplicate and the target genes were normalized to the GAPDH expression levels. The primer sequences of the RT-PCR and qRT-PCR are listed in Supporting Information Table S2 .
Immunocytochemistry
Cells were fixed with PBS containing 4% paraformaldehyde for 10 minutes at room temperature. After washing with PBS, the cells were treated with PBS containing 5% donkey serum, 1% bovine serum albumin (BSA, WAKO) and 0.1% Triton X-100 for 45 minutes at room temperature. The cells were incubated with primary antibodies 48C overnight and then stained with secondary antibodies. The primary antibodies included Sendai virus (MBL, Nagoya, Japan, PD029), OCT3/4 (BD, 611202), NANOG (R&D Systems, AF1997), b-III-tubulin (Chemicon, Billerica, MA, MAB1637), a-SMA (DAKO, Santa Clara, CA, M0851) and SOX17 (R&D systems, AF1924). All the secondary antibodies (Alexa Fluor 594-conjugated anti-rabbit, -mouse, -goat IgG and Alexa Fluor 488-conjugated anti-mouse, -goat IgG were obtained from Life technologies. Hoechst 33342 (WAKO) was used for nuclear staining.
Microarray Experiments and the PluriTest
Biotinylated cRNA was prepared from 100 ng of total RNA using a GeneChip 3'IVT PLUS Reagent kit (ThermoFisher Scientific, Waltham, MA) and was hybridized to the GeneChip PrimeView Human Gene Expression Array (ThermoFisher Scientific) for 16 hours at 458C. Array slides were washed and stained in an Affymetrix Fluidics station 450, and scanned using a GeneChip scanner 3000 7G system. The data files were then uploaded to www.pluritest.org, scored for pluripotency, and deposited into the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database with accession no. GSE104605.
Karyotype Analyses
The G-band karyotype analysis for gdT-iPSC was performed at Chromocenter, Inc. (Yonago, Japan).
In Vitro Spontaneous Differentiation via Embryoid Body Formation
For embryoid body (EB) formation, undifferentiated iPSCs were dissociated into single cells, resuspended in Primate ES medium (Reprocell) containing 20 mM Rho-associated kinase (Rock) inhibitor Y-27632 (WAKO) and seeded on low-cell-adhesion 96-well spindlebottom plates (PrimeSurface, Sumitomo Bakelite, Tokyo, Japan, MS-9096M) at a density of 1 3 10 4 cells per well. After 7 days of culture, the EBs were transferred to gelatin-coated 24-well plates and were cultured in the same medium for another 8 days. The differentiated cells were immune-stained with the indicated antibodies.
Differentiation of Human cdT-iPSCs into Hematopoietic Progenitor Cells In Vitro
Prior to differentiation, single dissociated undifferentiated human gdT-iPSCs were seeded onto a Laminin511-E8-coated 6-well plate at a density of 2 3 10 3 cells and cultured in Stem Fit medium. When individual colonies grew to around 500 mm in diameter, the medium was replaced by Stem Fit medium supplemented with 4 mM of CHIR99021 (Tocris Bioscience, Bristol, UK), 80 ng/ml of rhBMP4 (R&D Systems) and 80 ng/ml of rhVEGF (R&D Systems). This day was defined as day 0 of our protocol. On day 2, the medium was refreshed. On day 4, the medium was replaced by Essential 6 medium (ThermoFisher Scientific) supplemented with 4 mM of SB43152 (WAKO), 80 ng/ml of rhVEGF, 50 ng/ml of rhbFGF (Reprocell) and 50 ng/ml of rhSCF (R&D Systems). On day 6, the medium was replaced by StemPro-34SFM (Thermo Fisher Scientific) supplemented with 20 ng/ml of rhVEGF, 50 ng/ml of rhSCF, 50 ng/ml of rhIL-3 (R&D Systems), 50 ng/ml of hIL-6 (Roche, Basel, Switzerland), 50 ng/ml of rhFlt3 ligand (R&D Systems) and 10 IU/ml of recombinant human Erythropoietin a (EPO) (Kyowa Hakko Kirin, Tokyo, Japan). On day 8, the medium was replaced by StemPro-34SFM supplemented with 50 ng/ml of rhSCF, 50 ng/ml of hIL-6 (Roche) and 10 IU/ml of EPO. On day 10, the medium was refreshed. Cultures were maintained at 378C in a humidified atmosphere containing 5% CO 2.
RESULTS
cdT Cell-Dominant Gene Transduction in Whole PBMC Culture gdT cells, which represent a small subset (1-5%) of the T cell population, have been reported to be activated with zoledronate (Zol) and interleukin (IL)-2 [9] . To confirm this, we stimulated whole PBMC culture with Zol/IL-2. We observed that cell aggregates formed and gradually grew, suggesting that some types of cells in culture were activated (Fig. 1A) . We then examined whether gdT cells were dominantly activated by flow-cytometry. CD3 and TCR Vg9 co-staining revealed that after 13 days of culture, a large portion-but not all-of the cultured cells were gdT cells with TCR Vg9 expression (Fig. 1B) ; the percentages in three independent experiments were 81.6%, 79.8%, and 96.8%. These data indicated that we successfully activated gdT cells in whole PBMC culture.
We next examined whether Sendai virus-mediated gene transfection into whole PBMC culture stimulated with Zol/IL-2 resulted in the transgene expression in a gdT cell-dominant manner, because the Sendai virus was previously reported to specifically and efficiently transduce a foreign gene in activated murine and human T cells, but not in naive T cells [28] . We infected Zol/IL-2-stimulated whole PBMC culture with SeV vector expressing the blue fluorescent protein (BFP) gene on day 4 and analyzed the cells on day 6. We observed the expression of BFP under fluorescence microscopy (Fig. 1C) . In a representative experiment, the proportions of CD31/TCR Vg91 cells (gdT cells), CD31/TCR Vg92 cells (abT cells) and CD3-/TCR Vg92 cells (B cells and monocytes) were 32%, 63%, and 5%, respectively, and the proportions of BFPpositive cells in the CD31/TCR Vg91 cells, CD31/TCR Vg9 cells and CD3-/TCR Vg92 cells were 78.8%, 0.6% and 10.5%, respectively (Fig. 1D) . The data of three independent experiments are shown in the Fig. 1E -G. The proportion of BFP-positive cells (Fig.  1E ) and the mean fluorescence intensity (MFI) of BFP (Fig. 1F) in the CD31/TCR Vg91 cells were much higher in comparison to the CD31/TCR Vg92 cells and CD32/TCR Vg92 cells. Furthermore, even among BFP-positive cells, the MFI of BFP in the CD31/TCR Vg91 cells was higher than that in the other subsets (Fig. 1G) .
Taken together, we successfully demonstrated that a combination of Zol/IL-2-stimulation and Sendai virus vectors allowed for gdT cell-dominant gene transduction in whole PBMC culture without cell sorting. Based on this finding, we conceived a novel strategy for (Fig. 1H) , in which the dominancy of gene transfer into desired cells, but not purity of the desired cells, allows for the generation of iPSCs with certain antigen-specific TCR genes.
Generation of Human cdT Cell-Derived iPSCs from Whole PBMC Culture
To generate iPSC lines from gdT cells, we transfected SeV vector encoding the OCT3/4, SOX2, KLF4, and c-MYC reprogramming factors into whole PBMC culture stimulated with Zol/IL-2 and subsequently cultivated the cells under human ESC conditions ( Fig. 2A) . After 3-4 weeks, we observed the emergence of human ESC-like and non-ESC-like colonies (Fig. 2B, Supporting Information Fig.  1A ). The numbers of hES-like colonies/total colonies at 21 days post SeV-infection were 0/0, 51/59, 40/49, 36/48 in dishes at MOIs of 0, 10, 20, 30, respectively. We picked up several human ESC-like colonies and expanded the cells, thereby establishing 19 iPSC lines in an experiment.
To examine the rearrangement at the TCRG and TCRD gene locus in these cell lines, we performed a genomic PCR. In 13 of the 19 iPSC lines, rearrangements of the TCRG and TCRD genes were identified as single bands representing Vg9-to-JP and Vd2-to-Jd1 or -Jd3 recombination, which indicated that these cell lines carried Vg9Vd2-TCR genes (Fig. 2C) . In one line (46B4) we detected both bands, which represented Vd2-to-Jd1 and Vd2-toJd3 recombination. The analysis of single-cell sub-clones derived from the 46B4 showed that the line was a mixture of clones harboring Vd2-to-Jd1 and Vd2-to-Jd3 recombination (data not shown). In addition, we also established iPSC lines from two other healthy donors using the same procedure, and reproducibly obtained iPSC lines carrying Vg9Vd2-TCR genes (Supporting Information Fig. 1B, 1C) ; these were named the gdT-iPSC lines.
Moreover, we determined the sequence of complementarity determining regions 3 (CDR3) of the TCRG and TCRD gene regions in the 14 established gdT-iPSC lines, and identified a set of productive gene rearrangement in those cell lines ( Fig. 2D ; Table 1 ).
Characterization of cdT Cell-Derived hiPSCs
The three established gdT-iPSC lines (46A1, 46B1, 46C2) showed a human ESC-like morphology (Supporting Information Fig. 2A ). We first examined whether SeV remained in the lines by RT-PCR and immune-staining with anti-SeV antibodies. At passage 5, almost all of the colonies in the three lines were positive for SeV vector (Fig.  3A, Supporting Information Fig. 2B ). We then cultured these lines at 398C for 5 days, since the SeV vector carries temperaturesensitive mutations that enable the removal of the residual vector by shifting to a non-permissive temperature (388C-398C). Consequently, there was an obvious decrease in the proportion of SeVpositive colonies; however, it did not disappear (data not shown).
We therefore performed sub-cloning and expanded them to obtain SeV-free iPSC lines. An RT-PCR and immunostaining revealed that we could obtain SeV-free subclones (46A1-s3, 46B1-s1, and 46C2-s4) from the SeV-positive parental lines (Fig. 3A , Supporting Information Fig. 2B ). These subclones were used for the following assays. We next evaluated the stem cell marker expression of the gdT cell-derived lines by an RT-PCR and immunostaining. The RT-PCR showed that these lines, like a conventional iPSC line (409B2) [29] , expressed the mRNAs of typical ES cell markers such as OCT3/4, NANOG, SOX2, REX1, DNMT3B, and LIN28 (Fig. 3B, Supporting  Information Fig. 2C ). Immunostaining revealed that these lines expressed OCT3/4 and NANOG at the protein level (Fig. 3C) . The 46A-1-s3 line was confirmed to have a normal 46XX karyotype by the G-band technique (Supporting Information Fig. 2D) .
To examine the differentiation potential of gdT-iPSCs in vitro, we performed a differentiation assay via EB formation. The gdTiPSCs (46A1-s3 and 46C2-s4) were able to form EBs during suspension culture (data not shown). After subsequent attached culture for 8 days, we found cells that were positive for b III-tubulin (ectoderm), a-smooth muscle actin (a-SMA, mesoderm) and SOX17(-endoderm) (Fig. 3D) , indicating that the gdT-iPSCs could differentiate into three germ layers in vitro. Additionally, we performed a PluriTest, which is a robust open-access bioinformatics assay to investigate pluripotency based on gene expression profiles [30] . The analysis of these two gdT-iPSCs and a conventional iPSC line (409B2) [29] by the PluriTest algorithm revealed that all the three lines were pluripotent and were similar to validated normal hPSCs; this was indicated by a Pluritency Score of >20 (y-axis) and a Novelty Score of <1.67 (x-axis) (Fig. 3E) .
Furthermore, to reconfirm that the iPSC lines were derived from gdT cells and not abT cells, we performed a DNA fragment analysis by the capillary electrophoresis of the PCR products for the TCRG and TCRB gene regions. The lines showed a specific peak for Vg-to-Jg recombination, but not for Vb-to-Jb1/Jb2 recombination (Fig. 3F) . These data demonstrated that the gdTiPSCs were absolutely derived from gdT cells and retained the same TCR genes as the original cells.
Redifferentiation of cdT-iPSCs into the Hematopoietic Lineage
To test the hematopoietic differentiation potential of the gdT-iPSCs, we examined whether or not gdT-iPSCs could generate CD341/ CD431 hematopoietic progenitor cells. We referred to and modified some previously reported methods [31] [32] [33] and established a hematopoietic differentiation protocol starting from iPS cell culture in Stem Fit medium on lamin-511 E8 fragment (Fig. 4A) . Two gdTiPSC lines (46A1-s3 and 46C2-s4) underwent differentiation with the protocol. On day 4, around two-thirds of cells expressed APJ, an early hematovascular precursor marker [34] [35] [36] , also known as APLNR (Fig. 4B) . Flow cytometry on day 12 revealed that the gdTiPSC lines were able to generate CD341/CD431 hematopoietic progenitor cells efficiently; CD34/CD43 double-positive cells accounted for more than 70% and 40% of the gdT-iPSC-46A1-s3-and gdT-iPSC-46C2-s4-derived cells, respectively (Fig. 4C) .
DISCUSSION
In the present study, we generated gdT cell-derived iPSCs. Several previous studies have reported the generation of iPSCs from abT cells (abT-iPSCs), raising the expectation that it will be possible to develop novel iPSC-based cancer immune-therapies [21, 22] . However, a abT-iPSC line can only be used for a limited number of cancer patients due to the MHC-restriction of abT cell clones. In contrast, gdT cells exhibit MHC-unrestricted lytic activity against a wide variety of tumor cells [6, 7] . Thus, one gdT cell-derived iPSC line can be used for a large number of patients. From the point of view of commercialization, which is one of the essential factors for the practical application of iPSC-based therapy, one gdT-iPSCbased product could have a much larger market than one abTiPSC-based product. One of the obstacles to the development of iPSC-based therapies is the high development and production costs [37] . Thus, gdT-iPSC-based immunotherapy might be one of the most promising projects in terms of its clinical translation.
We generated iPSCs from the desired type of cells, or gdT cells without cell collection using a cell sorter. In contrast, conventional technologies for generating iPSCs from a particular cell types requires cell sorting with HLA-peptide multimer or antibodies [21, 22] . With reference to clinical applications, we should be concerned about the potential unknown effects of unintended residual materials that are used in the production process-including antibodies or HLA-peptide multimer, which are used for the selection of the desired cells. Our novel technology could avoid this concern because both IL-2 and Zoledronate have already been used in clinical practice.
Our novel strategy, in which the dominancy of gene transfer into the desired cells, but not the purity of the desired cells, allowed us to obtain iPSCs that were derived from particular cell type. It might be possible to apply this technology to generate iPSCs from various types of cells. Some previous reports have suggested that the differentiation propensity of iPSCs was influenced by their origin [38] [39] [40] . This phenomenon is understood to be due, at least in part, to the epigenetic memory of the original somatic cells in iPS cells [41] ; thus, researchers might demand simple and clinically applicable technologies for generating iPSCs that use various cells (including T cells) according to the target cell type of the iPSC derivatives. In the current study, we used a combination of gdT cell-dominant activation using with Zol/IL-2 and activated T cell-dominant gene transfer using a SeV vector to generate the gdT-iPSCs. In the future, other methods should be developed according to the types of cells that are desired.
In the present study, we determined the CDR3 sequences of the rearranged TCRG and TCRD gene regions and confirmed that iPSC lines were successfully generated from several different gdT cells. The recognition of antigens by gd-TCRs is known to depend on the sequence of its peptide, especially that of CDR3 [42] . In addition, a recent report revealed that gd-TCRs recognized tumor antigens via the CDR3d region [43] and CDR3d-grafted Vg9Vd2 T Watanabe, Koyanagi-Aoi, Taniguchi-Ikeda et al. 41 www.StemCellsTM.com O c 2017 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by cells (peripheral blood lymphocytes expressing the g9d2-TCR with a tumor antigen-specific CDR3d region) exhibited cytotoxicity against tumor cells [44] . However, it has been difficult to determine the precise sequence of the CDR3d region that exhibits the most effective antitumor activity. By assessing the antitumor activity of various gdT cell clones derived from a range of gdT-iPSC lines with various CDR3 regions, we might be able to determine the gdT cells that have the most effective antitumor activity. Thus, in comparison to conventional adoptive immunotherapy, gdT-iPSCs could provide both a source of near limitless and rejuvenated cells and more effective source of cells for cancer immunotherapy.
CONCLUSION
In summary, the results of the present study provide an efficient and convenient method for generating gdT-iPSCs with the potential to differentiate into hematopoietic progenitor cells. Our technology will pave the way for new avenues for developing novel immune therapies that are applicable for various types of cancer. 
